Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis : Clinical and Laboratory Correlates of Remission Duration by Simonini, Gabriele et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/acr.23435 
This article is protected by copyright. All rights reserved. 
Article type      : Original Article 
 
FLARES AFTER WITHDRAWAL OF BIOLOGIC THERAPIES IN JUVENILE 
IDIOPATHIC ARTHRITIS: CLINICAL AND LABORATORY CORRELATES OF 
REMISSION DURATION 
 
Gabriele Simonini M.D.1, Giovanna Ferrara M.D.2, Irene Pontikaki M.D.3, Erika Scoccimarro 
M.D.4, Teresa Giani M.D.5, Andrea Taddio M.D.2,6, Pier Luigi Meroni M.D.3, Rolando Cimaz 
M.D.1 
1 Anna Meyer Children Hospital and University of Florence, Italy; 2 University of Trieste, Italy; 3 
Gaetano Pini Institute and University of Milano, Italy; 4 University of Florence, Italy; 5 Anna Meyer 
Children Hospital, Florence, Italy, 6 Institute of Maternal and child health IRCCS “Burlo Garofolo” 
Trieste, Italy 
 
Subtitle: Risk of flare after withdrawing biologic therapies in JIA 
 
Keywords: juvenile idiopathic arthritis, flare, biologic therapies, remission duration 
 
Address correspondence to: 
Rolando Cimaz, MD Anna Meyer Children Hospital and University of Florence, Italy tel +39 055 
5662924; email:  rolando.cimaz@meyer.it 
 
The authors declare no conflict of interest and received no financial support with regard to the work 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Abstract 
Objective: to assess the time in remission after discontinuing biologic therapy in JIA patients. 
Methods: we enrolled 135 patients followed in three tertiary care centers. Primary outcome was to 
assess, once remission was achieved, the time in remission up to the first flare after discontinuing 
treatment. Mann–Whitney U-test, Wilcoxon signed-rank test for paired samples, chi-square, and 
Fisher’s exact test were used to compare data. Pearson and Spearman correlation tests were used to 
determine correlation coefficients for different variables. In order to identify predictors of outcome 
Cox regression model and Kaplan–Meier curves were constructed, each one at mean of entered 
covariates. 
Results: The majority of enrolled patients flared after stopping treatment with biologics (102/135, 
75.6%) after a median follow-up time in remission off therapy of 6 months (range 3–109). A higher 
probability of maintaining remission after discontinuing treatment was present in systemic onset 
disease compared to the rest of JIA patients (Mantel-Cox χ2 8.31, p<0.004). In analysis limited to JIA 
children with polyarticular and oligoarticular disease, patients who received biologics > 2 years after 
achieving remission had a higher probability of maintaining such remission off therapy (18.64 ±3.3 
months vs 11.51 ±2.7, p<0.009; Mantel-Cox χ2 9.06, p<0.002). No other clinical variable resulted 
significantly associated with a long-lasting remission. 
Conclusion: Children with oligoarticular and polyarticular JIA who stop treatment before 2 years from 
remission have a higher chance of relapsing after biologic withdrawal. 
 
Significance and Innovations 
1) The majority of patients with juvenile idiopathic arthritis flared after stopping biologic 
therapy. 
2) Patients with systemic JIA are less likely to flare after withdrawal of biologic therapy. 
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3) Patients with oligoarticular and polyarticular JIA who stop treatment before 2 years from 
remission achievement have a higher chance of relapsing after biologic withdrawal. 
 
Introduction 
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and includes a 
heterogeneous group of arthritis of unknown aetiology with onset before the age of 16 years that 
persist for > 6 weeks (1). JIA is classified according to the revised ILAR criteria (2) into seven 
categories. The severity of disease and long-term outcome are variable between different JIA 
categories, and even within the same type, between different individuals. Studies have shown that at 
least one third of patients may require treatment into adulthood (3,4). With modern treatment and 
especially biologic treatment, the objective of the management of JIA is to achieve inactive disease, 
which should persist for the longest period, and in current practice, this is obtained in a high 
percentage of cases overall, with the exception of RF-positive polyarthritis and systemic onset disease 
(5). Many patients discontinue antirheumatic treatment, but most of them experience a recurrence of 
disease. Since prolonged treatment of patients with inactive disease may result in unnecessary 
exposure to adverse effects, the identification of clinical features associated with an increased risk of 
recurrences would be helpful in driving the choice of duration therapy. While some information in this 
regard exist for second-line drugs (eg methotrexate), studies on biologic therapy are lacking. 
The aim of our study was therefore to assess the remission duration after discontinuing biologic 
therapy in a retrospective multicenter cohort of patients with JIA, and to identify possible correlates 
with risk of subsequent flares. 
Materials and Methods  
We designed a multicentre, retrospective analysis of clinical chart data from three tertiary paediatric 
rheumatology centres in Italy (Anna Meyer Children Hospital - Florence, Gaetano Pini Institute - 
Milano and Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste). 
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Inclusion criteria  
To be considered eligible for this study, patients were required to have, at the time of enrolment: 1) 
JIA diagnosis according to ILAR criteria (2); 2) inactive disease after a first cycle of any biologic 
treatment, single or in combination therapy, for at least 6 months; 3) discontinued all treatments 
(including DMARDs) for at least 3 months; 4) age at the time of biologic treatment onset < 18 years, 
since we aimed to provide data limited to the paediatric age. 
Main outcome measures 
The primary outcome of this study was to assess, once remission on medication was achieved, the 
time to the first relapse after discontinuing treatment. In addition, secondary outcomes were, once 
biologic drug was started, time to achieve disease remission on medication, time to biologic 
discontinuation, time in remission on medication before discontinuing all treatments. Clinical and 
laboratory correlates of remission duration were evaluated.  
Clinical remission on medication was defined as a persistent inactive disease for a minimum of 6 
continuous months as for Wallace criteria (6). Inactive disease was defined as: 
1) absence of joints with active arthritis, 
2) absence of systemic manifestations (fever, rash, serositis, splenomegaly or generalized 
lymphadenopathy attributable to JIA-systemic onset),  
3) absence of active uveitis,  
4) absence of enthesitis (for ERA),  
5) normal ESR or CRP  
6) and, in any case, if PGA indicates no disease activity (VAS=0)  
A modification of the more recent Wallace criteria for inactive disease (7) was introduced since we 
did not consider the morning stiffness as a criteria, considering it too vague. A flare was considered 
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when there was loss of at least two of the previous criteria and, in any case, when the treating 
physicians decided treatment intensification due to a significant flare (5).  
Analysis plan  
Chart review has been performed between September 2015 and March 2016. Data extracted from 
clinical charts included: demographic variables, JIA category, laboratory parameters of inflammation 
and antinuclear antibody positivity (titer > or = 1:160, in two consecutive collections), number of 
active joints at start of biologic drug, associated uveitis, corticosteroid concomitant and previous 
usage, DMARDs concomitant and previous usage, type of biologic administered, time interval 
between diagnosis and the initiation of biologic therapy, time to achieve remission once biologic drug 
was started, time in remission on therapy before discontinuing all treatments, cumulative time on 
biologic, time in remission off therapy, therapeutic decision upon flare and follow up time. 
Since anonymized data were used and the study was retrospective, according to national regulations 
no ethics committee approval was required. 
Statistical analysis 
All results are expressed as mean ± S.D or median, range. Mann–Whitney U-test, Wilcoxon signed-
rank test for paired samples, chi-square tests, and Fisher’s exact test, when appropriate, were used to 
compare data.  An a priori power analysis was completed using G Power program (8). Two-tailed p 
values were employed. Considering the epidemiology of JIA a large expected difference was 
estimated for the sample:  the effect size f = 0.40, as per Cohen (9). In addition, power was set at 0.95, 
meaning there would be a 95% probability of reaching statistical significance if the obtained 
differences were truly present in the population. Results from the power analysis showed that 120 
participants would be required. 
The following data, entered into a customized JIA database, were considered as variables for 
correlations, and as covariates for the survival curves: age at study entry, age at initiation of biologic 
therapy, gender, associated uveitis, disease duration, age at JIA onset, active arthritis duration, time 
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interval between disease onset and initiation of biologic drug, type of therapy administration (number 
and frequency), concomitant medications, previous cumulative corticosteroid dose and its duration, 
previous DMARD treatment duration, number of previous flares, ANA presence, time to obtain 
remission, time in remission on therapy, time in remission without therapy, cumulative time on 
therapy, and follow-up time. Before each eligible subject was recruited, an inclusion criteria second 
revision has been performed by the Florence centre, who acted as study coordinator and data 
management. Pearson and Spearman correlation tests were used to determine correlation coefficients 
for different variables. In order to identify predictors of outcome Cox regression model and Kaplan–
Meier curves were constructed, each one at mean of the above reported covariates. Non-parametric 
tests were used, where necessary, due to the small size of our groups and to the skewness of our data. 
Levels of p<0.05 were considered statistically significant. All analyses were performed on SPSS 
package for MAC, version 23.0 (SPSS, Inc., Chicago, IL, USA). 
 
Results 
Among 349 patients followed for JIA at the three tertiary care centers, between January 2000 and 
March 2016, and treated with biologics started before 18 years of age, 135 (38.6%, 104 female, 31 
male, median age 14.6 years, range 3.2-16.8) resulted eligible, since they achieved clinical remission 
on therapy for at least 6 months and could discontinue biologic treatment. 
Clinical characteristics of enrolled patients are reported in Table 1. Eighty-seven patients had received 
Etanercept, 27 Adalimumab, 12 Infliximab, 7 Anakinra, 1 Rituximab, and 1 Abatacept, each one 
administered at the current standard dose for JIA, for a median period of 20 months (range, 7-146).  
Ninety-two (68.1%) children also received concomitant administration of MTX treatment at standard 
dose 10-15 mg/m27week. 
The vast majority of enrolled patients flared after stopping treatment with biologics (102/135, 75.6%) 
with a median follow-up time in remission off therapy of 6 months (range 3–109). Among patients 
who flared, 34.1% restarted the same biologic, 19.3% switched to another biologic, 4.4% restarted 
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methotrexate, 11.9% underwent intra-articular corticosteroid injection, 2.2% did not receive any 
treatment, 0.7% received another anti-rheumatic medication.  
Considering the time point one year after treatment discontinuation 42/135 (31.1%) patients were still 
in remission [Figure 1]. For patients who were still in remission after discontinuation, remission lasted 
for a median period of 53 months (range 12-109): 17/48 with polyarticular onset, 7/27 oligoarticular 
extended, 6/35 oligoarticular persistent, 2/6 enthesitis-related arthritis, 2/7 psoriatic arthritis, and 8/12 
systemic onset JIA. Stratifying by JIA categories, Kaplan-Meier curves showed an overall difference 
among different types of JIA (Mantel-Cox χ2 12.47, p<0.02), with systemic onset disease showing a 
higher probability of maintaining clinical remission off therapy when compared to the rest of JIA 
patients (Mantel-Cox χ2 8.31, p<0.004) [Figure 2].  
Due to the non homogeneous distribution across JIA categories in our enrolled population, and the 
known different genetic backgrounds and response to therapy among them, in order to identify 
potential correlates with the main outcome we limited analysis to 106 children with polyarticular and 
oligoarticular disease, thus excluding systemic JIA, RF-positive, enthesitis-related arthritis and 
psoriatic categories. 
In this analysis ANA positivity was not associated with a higher probability of flare (Mantel-Cox χ2 
0.08, p= .77). Children who received biologic therapy for more than 2 years after achieving remission, 
thus a clinical remission on therapy longer than 2 years, had a higher probability of maintaining 
clinical remission off therapy compared to children who received biologic therapy for less than 2 
years after achieving remission (Mantel-Cox χ2 9.06, p<0.002) [Figure 3] and mean time on clinical 
remission off therapy resulted significantly higher (18.64 ±3.3 months vs 11.51 ±2.7, p<0.009). 
Stratifying by 2 years of biologic treatment duration, once achieved remission, 14 (87.5%) of 16 
children were still on remission after treatment discontinuation compared to 2 (12.5%) of 16 children; 
whilst 36 (40 %) of 90 children compared to 54 (60%) of 90 flared again after treatment 
discontinuation (Mantel-Haenszel  χ2 10.36, p <0.001) [Figure 4]. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Conversely, our analysis failed to identify other time durations such as 6, 12 and 18 months of clinical 
remission on therapy as predictors of flare.  
No other variable, including total length of treatment, type of biologic treatment and concomitant 
administration of MTX, resulted significantly predictors of long-lasting remission without therapy. 
 
Discussion 
In the last two decades, novel therapies, and especially the TNF-blocking agents, have improved the 
remission rate in JIA, with the majority of patients achieving clinical remission and many 
discontinuing therapies. 
In our study, we found that 37.8% of patients affected by JIA discontinued biologic drug for persistent 
inactive disease, after a median of 20 months from biologic onset, but that most of them relapsed. 
Guzman et al (5) reported that the probability of discontinuing all medications was 43%, which is 
similar to what we found in the present study.  
Despite achieving clinical remission, we found that most children with JIA flared after discontinuing 
therapy. However, this is hardly surprising, since it has already known that neither MTX nor biologic 
therapies for JIA normalize immune function (10).   
To our knowledge, our one is one of the few studies to deal with the probability of flares after 
stopping therapy. A prospective French study (AJIBIOREM, clinicaltrials.gov NCT02840175) has 
been planned but not yet recruiting. The study will investigate if the early tapering and then 
withdrawal of biological agent, in a homogenous group of children with juvenile idiopathic arthritis 
achieving inactive disease, is safe and not inferior to the maintenance of stable treatment intensity 
over 24 weeks. Even if retrospective, our study seems to underscore that stopping biologics after 
achieving remission before two years of continued treatment might be a risk for JIA children to a 
higher chance of relapse: patients in remission for >2 years on biologics were likely to sustain 
remission longer than those with < 2 years of remission. The caveat in our case is that the comparison 
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arms were not randomized, so the group that successfully sustain 2 years of remission may represent 
an intrinsically better-prognosis group. Foell et al. (11) reported a probability of flare within 12 
months of stopping therapy of 39.6%, similar to that of Guzman et al. (12) of 31.7%. In our study one 
year after therapy discontinuation, only 31.9% of patients were still in remission, so the probability of 
flare is higher then previous reported but similar to that of Chang et al. (63%) (13). This difference 
could be explained with differences in diagnostic criteria of flare and in treatment attitudes across 
studies. In fact, we used for the definition of inactive disease a PGA of 0, and not < 10 as Guzman, 
and also requested normal levels of acute phase reactants, differently from Guzman. The use of 
biologic drugs, and consequently a more severe disease, could explain the difference with the results 
of Foell, who analysed only patients treated with methotrexate.  
 
In our study, among different JIA categories, children with systemic JIA had the lowest probability of 
flares, compared to the other categories, particularly polyarticular or extended oligoarticular groups. 
Among patients affected by systemic JIA who flared, most were older patients who received TNF-
blocking agents,that are known to be less effective in this disease compared with other JIA categories. 
In addition, it is known that systemic JIA encompasses different genetic background and response to 
therapy from the other JIA categories (1).  
 
Guzman et al. (12) recently analysed risk factors for flare after stopping biologic therapy, finding that 
children with RF-positive polyarthritis had the highest probability of flare and children with systemic 
JIA the lowest. The prognosis of systemic JIA differs among studies (14,15); this is important with 
regard to our results since the natural history of the disease can be a confounding factor in that 
spontaneous remission can occur in a substantial percentage of patients. However, our results seem in 
accordance with Guzman, despite the low number of RF-positive and the relatively high number of 
polyarticular and extended oligoarticular patients in our cohort.  
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Iglesias et al. (16) in a cohort of non-systemic JIA found no relationship between JIA type and ANA 
positivity with the percentage of relapse after TNF-blocking discontinuation. Our analysis, not 
including systemic JIA as well RF, ERA and psoriatic children showed similar results: ANA 
positivity was not associated with a higher probability of flare. 
The design of our study did not have the chance to consider potential biomarkers related to a higher 
risk of flare. In previous studies Anink et al. (17) found that patients who flared within 6 months after 
discontinuation of etanercept had higher myeloid related protein (MRP8/14) levels at the time of 
discontinuation, compared to patients who did not have flares. Similar result had already been 
obtained by Foell et al. (11) who in a randomized clinical trial proved the safety of withdrawing 
methotrexate therapy after 6 (versus 12) months of stable remission. In addition to MRP8/14, also the 
phagocyte activation markers S100A12, has been identified as a predictive biomarker for the risk of a 
flare in a recent study of PRINTO group (18). 
Chang et al. (13) in a retrospective monocentric study involving patients with RF-positive and 
negative polyarthritis and ERA, recently found that patients who withdrew anti-TNF and continued 
MTX flared more than those who stopped MTX and continued anti-TNF (89 vs 12%). We found no 
difference in patients treated with biologic in combination with or without MTX with regard to 
disease flares.  
Our study, being a retrospective and multicentre chart review, has of course some limitations, eg the 
choice of starting biologic drug is not standardized across centres, the treatment plans and decisions to 
withdraw drug can result heterogeneous, and the JADAS was not available for all patients.  
However, the definition of flare was standardized and quite strict, as inclusion criteria to be enrolled 
and the follow-up schedule is the same in the three clinics. On the other hand, as far as we now, 
shared guidelines regarding treatment withdrawal are not yet available, thus limiting the chance to 
make homogeneous treatment decision in this setting across centres, mostly in a retrospective 
collection.   
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Furthermore, since the number of patients in certain JIA subtypes was too small to draw reliable 
conclusions, in order to identify potential clinical descriptor of relapse after stopping biologic 
treatment, we limited the analysis to the more homogenous groups with an equal distribution of ANA 
positivity across them.  
Another potential limitation of our study might be the exclusion from the eligible population of 
children with more than one biologic treatment cycle before achieving remission, thus potentially 
excluding children with a more refractory disease. We acknowledge this limitation; however, from a 
statistical point of view, in order to minimize sample bias and make as much possible homogenous 
comparisons in an heterogeneous population such as JIA, we attempted to compare JIA children with 
similar clinical disease history. In order to identify clinical predictor of relapse, several time variables, 
e.g. active disease duration, and time interval between disease onset and initiation of biologic drug, 
acted as covariates for calculating survival curves thus limiting their effect size on target outcome. 
In conclusion, even if in a retrospective study, we showed that patients with systemic onset disease 
are less likely to flare when compared to other categories, and that JIA children belonging to 
oligoarticular and polyarticular groups who stop treatment before two years of remission have a 
higher chance of relapsing after biologic withdrawal. These data seem to suggest that biologic 
treatment, in selected JIA categories, might be continued for at least 2 years after achieving clinical 
remission. 
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Figure Legends 
Figure 1: Kaplan-Meier curve showing the time up to the first relapse after discontinuing therapy 
among enrolled patients. 
Figure 2: Kaplan-Meier curves showing the difference in the time up to the first relapse after 
discontinuing therapy according to JIA categories.  
Figure 3: Kaplan-Meier curves showing the difference in the time up to the first relapse after 
discontinuing therapy according to the duration of therapy (< or >2 years) after achieving 
remission. 
Figure 4. Figure shows number and percentage of children on remission after treatment 
discontinuation compared to children who flared after treatment discontinuation, stratified by 2 
years of biologic treatment (Mantel-Haenszel  χ2 10.36, p <0.001)  
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 Poly RF-  Poly RF + Oly-Pers Oly- ext systemic ERA Psoriatic Total 
N° ptients (n, %) 44(32.6%) 4 (3%) 35 (25.9%) 27 (20%) 12 (8%) 6 (4.4%) 7 (5.2%) 135 
Female (n, %) 35 (79%) 3(75%) 29 (83%) 20 (74%) 8 (66%) 3 (50%) 6 (86%) 104  
Age at onset, years 
(median, range) 
6 
1-14 
11.5 
7-16 
2 
1-13 
3 
11-14 
4 
0.9-14 
9 
7-14 
3 
1-10 
4 
0.9-16 
Age at starting biologic 
(mean years SD) 
9.45 ±4.72 12 ±4.68 8.03 ±4.42 9.41 ±4.71 8.25 ±6.01 11.33 
±3.67 
6.57  
±2.57 
8.98 
±4.68 
N° active joints at 
starting biologic 
(median, range) 
7 
1-18 
7.5  
1-19 
6 
1-14 
2 
0-13 
7 
1-19 
2 
1-10 
5 
1-10 
5 
0-19 
Etanercept 36 2 18 23 2 1 5 87 
Adalimumab 4 0 14 3 0 5 5 27 
Infliximab 3 1 3 1 3 0 5 12 
Anakinra 0 0 0 0 7 0 0 7 
Rituximab 1 0 0 0 0 0 0 1 
Abatacept 0 1 0 0 0 0 0 1 
Follow up time on 
remission on therapy, 
months (median, range) 
23.5 
(6-109) 
25.5 
(24-61) 
22 
(7-86) 
16 
(8-77) 
18 
(7-86) 
11 
(6-37) 
24 
(9-36) 
22 
(6-109) 
 
Follow up time on 
remission out of therapy 
months (median, range) 
6 
(3-92) 
60 
(13-89) 
6 
(3-75) 
4 
(5-109) 
15.5 
(7-93) 
7.5 
(3-50) 
7 
(4-32) 
6 
(3-109) 
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